41 completed, 7 terminated, 5 unknown, 3 recruiting. 58 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 58 | Completed 41, Terminated 7, Unknown 5, Recruiting 3, Not yet recruiting 2 |
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Terminated 1 |
Follow Hypopituitarism: new trials by email Literature Review of Hypopituitarism trials Research Report on Hypopituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201 - Growth Hormone Deficiency (GHD) | Phase 3 | Not yet recruiting | Lumos Pharma | 150 | 2027-02-01 | 2026-07-08 |
| GB06 Phase III Trial for Pediatric Growth Hormone Deficiency GB06, Norditropin®FlexProTM - Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children | Phase 3 | Recruiting | Kexing Biopharm Co., Ltd. | 192 | 2026-06-06 | 2026-06-10 |
| Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency LUM-201, Matched Placebo (Capsules) - Growth Hormone Deficiency (GHD) | Phase 3 | Recruiting | Lumos Pharma | 150 | 2026-05-20 | 2026-10-19 |
| Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency GB08, Norditropin NordiFlex - Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD) | Phase 2 / Phase 3 | Not yet recruiting | Shenzhen Kexing Pharmaceutical Co., Ltd. | 268 | 2025-08-31 | 2025-08-22 |
| Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) Somatropin, Placebo - Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury | Phase 3 | Recruiting | VA Office of Research and Development | 172 | 2025-01-13 | 2026-10-13 |
| A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency GenSci004, Genotropin - GHD | Phase 3 | Unknown | Changchun GeneScience Pharmaceutical Co., Ltd. | 162 | 2023-12-01 | 2023-09-11 |
| A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency PEG-somatropin - GHD | Phase 3 | Unknown | Changchun GeneScience Pharmaceutical Co., Ltd. | 180 | 2023-12-01 | 2023-09-11 |
| A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency Lonapegsomatropin - Adult Growth Hormone Deficiency, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 220 | 2021-12-16 | 2026-07-07 |
| A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is Macimorelin, Arginine, Clonidine - Growth Hormone Deficiency | Phase 3 | Completed | AEterna Zentaris | 101 | 2021-11-16 | 2024-08-12 |
| A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency Lonapegsomatropin, Placebo, Somatropin - Growth Hormone Deficiency, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 264 | 2020-12-03 | 2026-07-07 |
| Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency TransCon hGH, daily hGH - Growth Hormone Deficiency, Endocrine System Diseases | Phase 3 | Unknown | Visen Pharmaceuticals (Shanghai) Co., Ltd. | 150 | 2019-12-30 | 2020-03-30 |
| Treatment of GHD Associated With CHF Human growth hormone, Placebo - Heart Failure, Growth Hormone Deficiency | Phase 3 | Unknown | Federico II University | 64 | 2019-03-01 | 2019-02-15 |
| Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD Genotropin, somatrogon - Growth Hormone Deficiency | Phase 3 | Completed | Pfizer | 87 | 2019-02-07 | 2021-10-14 |
| Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children Y-shape pegylated somatropin, Norditropin®, Norditropin - Growth Hormone Deficiency | Phase 2 / Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 434 | 2018-12-26 | 2024-01-24 |
| A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial TransCon hGH - Growth Hormone Deficiency, Pediatric, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma A/S | 298 | 2017-12-19 | 2026-07-07 |
| Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency MOD-4023, Genotropin - Growth Hormone Deficiency | Phase 3 | Completed | OPKO Health, Inc. | 44 | 2017-12-07 | 2021-08-12 |
| A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency TransCon hGH - Growth Hormone Deficiency, Pediatric, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 146 | 2017-11-13 | 2026-07-07 |
| A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency Somavaratan - Growth Hormone Deficiency | Phase 3 | Terminated | Versartis Inc. | 21 | 2017-03-31 | 2018-03-09 |
| A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency somapacitan, Norditropin - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 3 | Completed | Novo Nordisk A/S | 62 | 2017-03-03 | 2020-11-23 |
| A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin - Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone) | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 162 | 2016-12-13 | 2026-07-07 |
Showing 20 of 58. Sign in to see all of them.
Dwarfism, Pituitary (57) · Endocrine System Diseases (6) · Pituitary Diseases (6) · Failure to Thrive (5) · Dwarfism (2) · Growth Disorders (2) · Brain Concussion (1) · Diabetes Mellitus (1) · Growth Hormone Deficiency With Pituitary Anomalies (1) · Heart Failure (1) · Obesity (1)
Brain Diseases (58) · Central Nervous System Diseases (58) · Hypothalamic Diseases (58) · Nervous System Diseases (58) · Bone Diseases (57) · Bone Diseases, Developmental (57) · Bone Diseases, Endocrine (57) · Musculoskeletal Diseases (57) · Dwarfism (55) · Endocrine System Diseases (52) · Pituitary Diseases (52) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)
Human Growth Hormone (29) · Growth Hormone (8) · lonapegsomatropin (3) · somapacitan (3) · MOD-4023 (2) · albusomatropin (2) · macimorelin (2) · somatrogon (2) · Anastrozole (1) · Arginine (1) · Blood Specimen Collection (1) · Capsules (1) · Citrullination (1) · Insulin (1) · Insulin-Like Growth Factor I (1)
Novo Nordisk A/S (8) · Pfizer (7) · Ascendis Pharma Endocrinology Division A/S (4) · Changchun GeneScience Pharmaceutical Co., Ltd. (3) · Eli Lilly and Company (3) · LG Life Sciences (3) · Versartis Inc. (3) · AEterna Zentaris (2) · EMD Serono (2) · Federico II University (2) · Lumos Pharma (2) · OPKO Health, Inc. (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Ascendis Pharma A/S (1) · BioPartners GmbH (1)
United States (25) · Japan (10) · France (9) · Germany (9) · Italy (9) · Poland (9) · United Kingdom (9) · Australia (8) · Greece (6) · Romania (6) · Slovakia (6) · Turkey (Türkiye) (6) · Ukraine (6) · Armenia (5) · China (5)
Will Charlton, MD (3) · HJ Ji, PhD (2) · Aimee Shu, MD (1) · Annamaria Colao, MD, PhD (1) · Bradley Miller (1) · Charlotte Hoeybye, MD (1)
PMID 36380045, PMID 18395480, PMID 16840832, PMID 19066295, PMID 20484474, PMID 21118739, PMID 22924571, PMID 24170106, PMID 24748824, PMID 28566441, PMID 29029101, PMID 29860473, PMID 30910221, PMID 32022863, PMID 32603494, PMID 34272849, PMID 35428884, PMID 36034448, PMID 39991735, PMID 40047762, PMID 41183961, PMID 41879875
2018 (3), 2014 (2), 2016 (2), 2004 (1), 2008 (1), 2015 (1), 2017 (1)